Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients ; volume:21 ; number:1 ; day:5 ; month:8 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cancer ; 21, Heft 1 (5.8.2021), 1-11, 12.2021
- Urheber
-
Masaki, Chie
Sugino, Kiminori
Kobayashi, Sakiko
Hosoi, Yoshie
Ono, Reiko
Yamazaki, Haruhiko
Akaishi, Junko
Hames, Kiyomi Y.
Tomoda, Chisato
Suzuki, Akifumi
Matsuzu, Kenichi
Ohkuwa, Keiko
Kitagawa, Wataru
Nagahama, Mitsuji
Ito, Koichi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08622-w
- URN
-
urn:nbn:de:101:1-2021103011301445820117
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Masaki, Chie
- Sugino, Kiminori
- Kobayashi, Sakiko
- Hosoi, Yoshie
- Ono, Reiko
- Yamazaki, Haruhiko
- Akaishi, Junko
- Hames, Kiyomi Y.
- Tomoda, Chisato
- Suzuki, Akifumi
- Matsuzu, Kenichi
- Ohkuwa, Keiko
- Kitagawa, Wataru
- Nagahama, Mitsuji
- Ito, Koichi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
Differentiated thyroid carcinoma in children: Clinical characteristics and long-term follow-up
Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms
Racial disparities of differentiated thyroid carcinoma: clinical behavior, treatments, and long-term outcomes
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
Differentiated thyroid carcinoma in children: Clinical characteristics and long-term follow-up
Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms
Racial disparities of differentiated thyroid carcinoma: clinical behavior, treatments, and long-term outcomes
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
Differentiated thyroid carcinoma in children: Clinical characteristics and long-term follow-up
Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms
Racial disparities of differentiated thyroid carcinoma: clinical behavior, treatments, and long-term outcomes
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States